Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab, Lenvatinib, and Paclitaxel-albumin in Advanced Gastric/GEJ Adenocarcinoma
NCT06030934Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Oct 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab, lenvatinib in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Fudan University. Status: unknown.
02
Drugs
envafolimablenvatinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06030934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06030934.